Ovation Science (OVAT) AI Stock Analysis

• Market Cap: C$1.06M
• Dividend Yield: N/A
• Average Volume (3M): 3.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.96
• Revenue Growth: -42.98%
• EPS Growth: 35.33%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 35,244,682
• 10 Day Avg. Volume: 3,400
• 30 Day Avg. Volume: 3,744
• PEG Ratio: 0.05
• Price to Book (P/B): -1.12
• Price to Sales (P/S): 10.81
• P/FCF Ratio: -6.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: C$0.03 ▼(-15.00% Downside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is primarily constrained by weak financial performance (ongoing losses, negative equity, and cash burn). Technical indicators add modest pressure with negative MACD and sub-50 RSI, while valuation remains unattractive due to loss-making status and no dividend support.

Positive Factors

Proprietary topical delivery platform

Ovation’s IntelliGel platform is a durable competitive asset: a technology backbone that can be applied across therapeutic and consumer skin-health products. A reproducible delivery platform supports licensing, partnerships, and product diversification, improving long-term revenue optionality and higher-margin opportunities.

2024 performance improved vs 2023

The company narrowed losses and grew revenue in 2024 versus 2023, signaling progress toward operational stabilization. If sustained, this trend lengthens runway, reduces urgency for dilutive financing, and indicates management can incrementally scale revenues while trimming loss drivers over a multi-quarter horizon.

Reduced cash burn in 2024

An improving cash-burn trajectory is a meaningful structural sign when persistent: reduced outflows in 2024 demonstrate cost control or revenue leverage beginning to take hold. Continued improvement would materially extend liquidity runway and lower solvency risk absent immediate external funding.

Negative Factors

Persistent operating and net losses

Sustained operating and net losses plus recurring negative cash flow materially constrain strategic flexibility. Over multiple quarters this forces reliance on external financing, increases dilution risk, limits R&D or commercial investment, and undermines the company’s ability to achieve self-sustaining growth absent a structural business change.

Negative shareholders' equity and rising debt

Negative equity and growing debt indicate balance-sheet stress that reduces borrowing capacity and creditor confidence. This structural weakness elevates insolvency risk, constrains capital allocation, and makes the company more vulnerable to adverse shocks or costly refinancing, limiting long-term resilience.

Deeply negative margins and volatile revenue

Volatile, materially reduced revenue and roughly -400% net margins reflect a business that cannot yet scale profitably. Such structural margin deficits mean even modest revenue growth won't translate to earnings without significant cost or model change, threatening sustainable cash generation and long-term viability.

Ovation Science Business Overview & Revenue Model

Company Description

Ovation Science Inc. engages in the production of cannabis or hemp products in Canada, the United States, and Mexico. The company's Invisicare is a patented drug delivery technology for use in topical and transdermal skin care products containing hemp seed oil and cannabis under the Ovation and BASKiN brands. It offers cannabidiol infused health and wellness solutions under the Invibe MD name; skincare solutions under the ARLO CBD name; and hand sanitizers under the DermSafe name. The company holds sublicenses for cannabis based products; and Lighthouse for licensed dispensaries in the United States. Ovation Science Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Ovation Science generates revenue through the licensing and sale of its proprietary Invisicare technology to pharmaceutical and skincare companies. This technology is used to create more effective topical and transdermal products, enhancing the performance of active ingredients. The company's revenue streams include royalties from licensed products, direct product sales, and potential partnership agreements with other companies looking to incorporate Invisicare into their own product lines. Collaborations with established industry players also play a significant role in driving the company's earnings.

Ovation Science Financial Statement Overview

Summary

Financial risk is high: persistent operating and net losses, ongoing negative operating/free cash flow, and negative shareholders’ equity in 2022–2024. 2024 showed improvement versus 2023 (higher revenue and smaller losses/cash burn), but the company remains far from break-even and appears dependent on external funding.

Income Statement

Revenue has been volatile and materially lower than prior years (down sharply from 2020 levels), despite a rebound in 2024 versus 2023. Profitability remains weak: operating results and net income are consistently negative across all years provided, with 2024 still showing deeply negative margins (roughly -400% net margin). A positive is that 2024 losses narrowed significantly versus 2023, but the business is still far from break-even.

Balance Sheet

The balance sheet shows significant stress with negative shareholders’ equity in 2022–2024, which is a major red flag and limits financial flexibility. Total assets are small and have declined versus earlier years, while debt has increased from 2022 to 2024. While the debt-to-equity figure appears negative due to negative equity (making it less informative), the key takeaway is elevated solvency risk given the capital structure.

Cash Flow

Cash generation is consistently negative: operating cash flow and free cash flow are below zero every year shown, indicating the company is consuming cash to fund operations. 2024 cash burn improved versus 2023, but free cash flow growth is sharply negative in 2024 and the business still lacks self-funding capacity. Overall, liquidity pressure remains a key risk unless external financing improves.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	64.71K	113.22K	61.93K	138.15K	224.95K	750.01K
Gross Profit	58.31K	85.72K	-251.43K	134.11K	-168.75K	548.02K
EBITDA	-402.84K	-404.15K	-778.83K	-786.73K	-2.39M	-1.16M
Net Income	-459.50K	-456.20K	-813.15K	-794.05K	-2.39M	-1.18M
Balance Sheet
Total Assets	39.56K	63.90K	76.89K	104.89K	769.90K	3.25M
Cash, Cash Equivalents and Short-Term Investments	5.55K	3.31K	48.85K	28.90K	647.56K	1.54M
Total Debt	275.51K	268.48K	192.62K	41.13K	0.00	0.00
Total Liabilities	1.33M	1.15M	728.99K	187.84K	63.74K	143.38K
Stockholders Equity	-1.29M	-1.09M	-652.10K	-82.95K	706.15K	3.11M
Cash Flow
Free Cash Flow	7.08K	-178.82K	-336.02K	-670.80K	-885.75K	-1.52M
Operating Cash Flow	7.08K	-178.82K	-336.02K	-670.80K	-885.75K	-1.39M
Investing Cash Flow	0.00	0.00	0.00	0.00	1.16M	-685.18K
Financing Cash Flow	709.00	133.28K	356.16K	47.24K	0.00	2.05M

Ovation Science Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OVAT, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 17.79 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:OVAT.

Ovation Science Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OILS	61 Neutral	C$10.13M	8.94	11.57%	―	-1.14%	―
VEXT	59 Neutral	C$64.40M	-6.17	-21.73%	―	43.56%	-349.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATLE	50 Neutral	C$56.36M	-2.79	-19.76%	―	26.91%	81.01%
LABS	45 Neutral	C$27.35M	-3.68	-19.10%	―	18.06%	34.58%
OVAT	43 Neutral	C$1.06M	-2.30	33.19%	―	-42.98%	35.33%
BNXT	42 Neutral	C$69.43M	-16.32	―	―	-62.34%	9.80%

Ovation Science Corporate Events

Ovation Science Wins Canadian Patent, Bolstering IP and Licensing Prospects for Topical Cannabis Line

Ovation Science has secured a new Canadian patent for its proprietary topical formulations containing CBD and THC, extending protection for its transdermal delivery technology beyond its existing U.S. patent and strengthening its international intellectual property portfolio. With patents now in both the U.S. and Canada, the company is better positioned to pursue exclusive licensing deals, strategic partnerships and premium product placement in two of the largest regulated cannabis markets, supporting recurring licensing revenue and long-term growth. The newly protected formulations, powered by Ovation’s Invisicare technology, have demonstrated significantly higher cannabinoid bioavailability compared with competing topical and oral products, reinforcing Ovation’s differentiated performance claims and making its platform more attractive to licensees across cannabis, wellness, pharmaceutical and beauty categories as regulatory frameworks evolve.

The most recent analyst rating on (TSE:OVAT) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Ovation Science stock, see the TSE:OVAT Stock Forecast page.

Ovation Science Grants 2.2 Million Stock Options to Directors and Officers

Ovation Science Inc. has granted 2.2 million stock options to its directors and officers, exercisable at $0.05 per share for two years from the grant date. The move strengthens equity-based incentives for the company’s leadership, potentially aligning management interests more closely with shareholders as Ovation advances commercialization of its patented Invisicare-based cannabinoid and skincare product portfolio in the wellness and beauty markets.

The most recent analyst rating on (TSE:OVAT) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Ovation Science stock, see the TSE:OVAT Stock Forecast page.